Login to Your Account



ODAC to weigh in on approving olaparib sooner than later

By Mari Serebrov
Washington Editor

Monday, June 23, 2014
Is a seven-month improvement in progression-free survival (PFS) in a subgroup of a single clinical trial enough to grant accelerated approval to Astrazeneca plc's olaparib as the first maintenance therapy for BRCA-mutated ovarian cancers?

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription